IAM
NVCT icon

Iridian Asset Management’s Nuvectis Pharma NVCT Stock Holding History

Iridian Asset Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.04M Buy
651,757
+65,437
+11% +$561K 2.04% 16
2025
Q4 		$4.43M Buy
586,320
+180,699
+45% +$1.18M 1.63% 23
2025
Q3 		$2.44M Buy
405,621
+32,904
+9% +$226K 0.96% 30
2025
Q2 		$2.78M Buy
372,717
+118,745
+47% +$1.08M 0.96% 29
2025
Q1 		$2.48M Buy
+253,972
New +$1.83M 0.78% 31
2024
Q4 		– Sell
-55,380
Closed -$348K – 53
2024
Q3 		$348K Buy
+55,380
New +$364K 0.07% 48

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Iridian Asset Management's NVCT Position: Q1 2026 in Review

Iridian Asset Management increased its Nuvectis Pharma (NVCT) stake by 11% in Q1 2026, buying an estimated $561K and bringing the position to 651,757 shares worth $5.04M. The position accounts for 2.04% of the portfolio, ranked #16.

Iridian Asset Management first reported a position in NVCT in Q3 2024 and has held it in 6 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Iridian Asset Management held 651,757 shares of Nuvectis Pharma worth $5.04M as of Q1 2026.
  • Iridian Asset Management bought 65,437 Nuvectis Pharma shares in Q1 2026, an estimated $561K.
  • Nuvectis Pharma made up 2.04% of Iridian Asset Management's portfolio in Q1 2026, its #16 holding.
  • Iridian Asset Management first reported a position in Nuvectis Pharma in Q3 2024 and has held it in 6 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.